Genfit stock tops SBF 120, a rebound ahead of tomorrow's results
The Lille-based biotech specializing in hepatic and metabolic diseases posts the most marked recovery on the SBF 120 this Monday morning, after several weeks of severe correction. The timing is peculiar: first-half 2026 results are expected tomorrow, Tuesday, September 29.
A 4.6% rebound that only partly corrects a monthly decline of 35%
Genfit advances 4.6% in trading, to €9.33, topping the SBF 120. This surge follows a particularly pronounced deterioration phase: the stock declined 35.74% over one month and remains down 19.29% over the past week. By this measure, today's rebound eases recent pressure without erasing a significant portion of it. Over twelve months, however, the stock still shows a performance of +198.1%, reflecting the extent of the bull cycle that preceded this correction. The stock is trading well below its short and medium-term moving averages: the MA20 at €12.27 represents a gap of nearly 24% above the current price, and the MA50 at €13.16 is approximately 29% above.
Only the MA200, at €9.42, remains close to the price, with a gap of less than 1%. The RSI, rebounding from its extreme oversold level from the previous session, remains at 24, still in a zone of marked selling pressure. Declared net short positions increased by 1.10 percentage points in one month, reaching 1.10% of capital, driven by two funds according to disclosed declarations. This rapid rise in shorts parallel to the stock's decline reflects increased institutional caution, though without signaling massive bearish conviction.
First-half 2026 results expected tomorrow, in a contrasting fundamental context
The publication of first-half 2026 results is scheduled for tomorrow, Tuesday, September 29. This is a milestone arriving in a contrasting fundamental context for Genfit. When first-quarter 2026 results were published (May 21, 2026), Iqirvo's commercial momentum was cited as a favorable factor for financial margins, while dependence on development partners remained identified as a risk.
On the valuation front, the consensus of surveyed analysts anticipates earnings per share that values the stock at approximately 10.9 times earnings for the following fiscal year, with the current fiscal year multiple remaining elevated at nearly 49 times. The biotech had moreover announced in September its intention to test nangibotide for acute decompensation of cirrhosis, and it had joined the CAC Mid 60 and SBF 120 indices of Euronext Paris as of September 18. The views of analysts on Genfit and the first-half figures expected tomorrow will be scrutinized to assess the strength of the business model and the evolution of cash, following a price decline that has brought the stock to its lowest levels in several months.
